Long non-coding RNA LINC01207 promotes cell proliferation and migration but suppresses apoptosis and autophagy in oral squamous cell carcinoma by the microRNA-1301-3p/lactate dehydrogenase isoform A axis

Xiaolin Lu, Liling Chen, Yang Li, Rong Huang, Xiangfeng Meng, and Fangfang Sun

ABSTRACT
Long noncoding RNAs (lncRNAs) have been reported to participate in the progression of various cancers, including oral squamous cell carcinoma (OSCC). This study aims to find out whether lncRNA LINC01207 regulates the progression of OSCC. Reverse transcription quantitative polymerase chain reaction (RT-qPCR) was conducted to evaluate gene expression in OSCC cells and tissues. Cell viability, proliferation, migration, apoptosis, and autophagy were detected using Cell Counting Kit-8 (CCK-8), colony formation, Transwell assays, flow cytometry, and western blot analysis. Luciferase reporter and RNA immunoprecipitation (RIP) assays were conducted to assess the interactions among genes. We found that LINC01207 was overexpressed in OSCC cells and tissues. LINC01207 silencing inhibited OSCC cell proliferation and migration but promoted apoptosis and autophagy, and LINC01207 overexpression had an opposite result. LINC01207 interacted with microRNA-1301-3p (miR-1301-3p) while lactate dehydrogenase isoform A (LDHA) was targeted by miR1301-3p. Effects caused by LINC01207 downregulation on OSCC cells were reversed by overexpression of LDHA. Overall, LINC01207 promotes OSCC progression via the miR-1301-3p/LDHA axis.

Introduction
Oral squamous cell carcinoma (OSCC), ranking the sixth most common cancer worldwide, accounts for more than 90% of head and neck cancer [1,2]. OSCC is prone to distant metastasis, such as lung metastasis, bone metastasis, lymphatic metastasis, and blood metastasis [3]. There are over 300,000 new cases of OSCC each year worldwide, and more than 140,000 patients die of OSCC each year [4,5]. Although great progress has been made to treat OSCC over the last years, the 5-year survival rate of OSCC patients has remained approximately 50% without any significant progress [6]. Hence, it is urgent to investigate novel clinical biomarkers that potentially function as targets for diagnosis or therapy of OSCC.

Autophagy is defined as the degradation of components via the autophagosome and lysosome [7,8]. The soluble autophagosome light chain 3 (LC3II) is the autophagosome related form (LC3II) during the autophagosome elongation process [9]. LC3II is degraded along with other components of autophagosome after fusion with lysosome. Therefore, the production of LC3II or the transformation of LC3 is regarded as indicator of autophagy activity [10]. Autophagy-related gene 7 (ATG7) composes part of the conjugation system involved in the redistribution of LC3II to the phagophore. The conjugation system consisting of ATG12-ATG5-ATG16 is pivotal for autophagosome elongation [11]. Evidence shows that autophagy is a major event in tumor progression [12].

Long noncoding RNAs (lncRNAs) consist of a subset of noncoding RNA transcripts that are more than 200 nucleotides in length [13–15]. LncRNAs play vital roles in gene regulation, genomic stability, survival, proliferation, and migration of cancer cells [16]. Studies have demonstrated that lncRNAs are closely related to the occurrence and progression of OSCC. For example, LINC00958...
promotes OSCC cell proliferation, induces cell death and reduces autophagy [17]. LncRNA SNHG20 regulates OSCC cell migration, invasion, and proliferation via the microRNA-19b-3p/RAB14 axis [18]. Given that OSCC is the most common type of head and neck cancer, we selected several lncRNAs that were reported to exert important effects in head and neck cancer for the purpose of investigating the role of lncRNA in OSCC. We successfully screened out LINC01207 as the most significantly upregulated lncRNA in OSCC tissues. LINC01207, located in the genomic 4q32 locus, is reported to be upregulated in some cancers, and its downregulation could inhibit tumor growth and promote apoptosis [19,20]. The ceRNA (competitive endogenous RNA) mechanism is a common post-transcriptional mechanism in which lncRNAs act as the endogenous sponge of microRNAs (miRNAs) to free the inhibition of miRNAs on message RNAs (mRNAs). It has been widely reported that lncRNAs regulate OSCC progression via the ceRNA pattern [21,22]. Additionally, LINC01207 promotes head and neck squamous cell carcinoma cell proliferation and stemness characteristics by acting as a ceRNA for miR-5047 [23]. LINC01207 contributes to prostate cancer progression by downregulating miR-1972 and upregulating LIM and SH3 protein 1 [24]. Therefore, we inferred that LINC01207 may function as a ceRNA in OSCC.

Lactate dehydrogenase A (LDHA) is a major molecular mediator of the Warburg effect and plays a critical role in the metabolism of tumor cells [25,26]. It has been reported that elevated expression of LDHA is a hallmark of many tumors and is associated with the clinicopathological features and survival outcomes of patients [27,28]. Inhibition of LDHA typically results in accelerated oxygen consumption, reduced cell malignant transformation and markedly delayed tumor formation, indicating the underlying role of LDHA in tumor initiation or maintenance [29].

In the present study, we are aimed at exploring the biological role of LINC01207 in OSCC. Due to its higher expression in tumor tissues than in normal tissues, we hypothesized that LINC01207 may play an oncogenic role in OSCC. Subsequently, a series of molecular experiments were performed to test whether LINC01207 acts as a ceRNA in OSCC. Our study may provide a promising therapeutic target for the treatment of OSCC.

Materials and methods

Tissue samples and cell lines

The OSCC samples (n = 30) and adjacent normal tissues (n = 30) were obtained from OSCC patients at Nanjing Stomatological Hospital Medical School of Nanjing University (Jiangsu, China) and then stored at −80°C. No other anticancer treatment was given to patients before the surgery. All patients provided written informed consent. This study was approved by the Ethics Committee of Nanjing Stomatological Hospital Medical School of Nanjing University (Jiangsu, China).

The OSCC cell lines, containing HSC-3 and HSC-4 cells, and human normal oral keratinocytes (NOK) cells were purchased from the Cell Bank of Chinese Academy of Science (Shanghai, China), and were incubated in Dulbecco’s Modified Eagle Medium (Gibco, Thermo Fisher Scientific, Inc., USA) added with 10% fetal bovine serum and 1% streptomycin (Sigma, St Louis, MO, USA). All the cells were maintained in a humidified atmosphere at 37°C containing 5% CO2.

Cell transfection

The short hairpin RNAs (shRNAs) targeting LINC01207 and nonspecific shRNAs (sh-NC), as well as pcDNA3.1-LINC01207/LDHA and empty vector were purchased from GenePharma (Shanghai, China). The miR-1301-3p mimics and negative control (NC) mimics were obtained from Genechem (Shanghai, China). HSC-3 and HSC-4 cells were seeded in 6-well plates at a density of 5 × 103 per well. When cell confluence reached 70–80%, the transfection was performed using Lipofectamine 3000 (Invitrogen, Carlsbad, CA, USA) for 48 h according to the manufacturer’s protocol [30].

Reverse transcription quantitative polymerase chain reaction (RT-qPCR)

Total RNAs were extracted using TRIzol reagent (Takara, Shiga, Japan) following the instructions of
manufacturer. First-strand cDNA was obtained from 2 μg total RNA using PrimeScript RT reagent (Takara). Subsequently, PCR was performed on SteponePlus Real-Time PCR Systems (Applied Biosystems, Foster City, CA, USA) with SYBR Green (Sigma) with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and U6 as internal references. The relative expression was calculated using the 2^(-ΔΔCt) method [31]. Primers used in RT-qPCR are as follows: GAPDH forward 5’-CATGAGAGTTGACAACGCTC-3’ and reverse 5’- GTCCCTCCAGATACAAAG-3’, U6 forward 5’- ATACAGAGAAAGTTAGCACGG-3’ and reverse 5’- GGAATGCTTCAAAAGAGTGTTGT-3’, LINC01207 forward 5’-CTGAGACTCTGTTGAATCAG-3’ and reverse 5’- AAACCTTCCACAGAAGCA-3’, miR-1301-3p forward 5’- TGCAAGCTGCGTGGAGTGACTTC-3’, LDHA forward 5’- TTCCAGTGTGCTGATGTTGG-3’ and reverse 5’- TTATCACCTCAAATCTGGTG-3’.

**Cell Counting Kit-8 (CCK-8) assay**

CCK-8 Kit (Beyotime, Shanghai, China) was used to assess cell viability as previously described [32]. After being transfected for 48 h, HSC-3 and HSC-4 cells (5000 cells per well) were seeded in 96-well plates. Next, 10 μl CCK8 reagent was added to each well at 0, 24, 48, and 72 h, respectively. A microplate reader (SpectraMax i3, Molecular Devices, USA) was utilized to detect cell viability by measuring the absorbance at 450 nm.

**Colony formation assay**

After the abovementioned transfection, HSC-3 and HSC-4 cells were seeded in 6-well plates (500 cells/well). After 14 days of incubation, the colonies were then fixed with 4% paraformaldehyde for 30 min and then incubated with 0.5% crystal violet (Beyotime, Shanghai, China) for 1 h at room temperature. And finally, the number of colonies with more than 50 cells was counted [33].

**Cell migration assay**

Cell migration was examined using Transwell inserts (pore size, 8.0 μm; Corning, USA) as previously described [34]. Briefly, 2 × 10^5 cells/well cells in 200 μl serum-free medium were suspended in the upper chamber, and the lower chamber was filled with 700 μl medium containing 15% fetal bovine serum. After 24 h at 37°C in an atmosphere containing 5% CO₂, the membranes in the lower chamber were fixed in 4% paraformaldehyde at room temperature and stained with crystal violet for 20 min. After washing, images of the cells on the membranes were captured under a light microscope in five randomly selected fields per sample.

**Flow cytometry**

Annexin V-fluoresceine isothiocyanate (FITC)/Prodim Iodide (PI) double-labeled staining kit (BD Biosciences, San Jose, CA, USA) was used in this assay. The procedure was performed as previously described [35]. The cells (2 × 10^5/well) in 6-well plates were collected, washed twice with cold phosphate buffered saline, and resuspended in 1 × binding buffer. Subsequently, cells were stained with 10 μl Annexin V-FITC for 15 min and 5 μl PI for 10 min in the dark at room temperature. Cells were examined using the FACSCanto II flow cytometer (BD Biosciences). Analysis of flow cytometry data was performed using FlowJo version X.10.0.7–1 (FlowJo, LLC).

**Western blot**

Western blot was performed using standard and established protocol as previously published [36]. Proteins were extracted from OSCC cells using radioimmunoprecipitation assay lysis buffer (Beyotime, Shanghai, China). Protein concentration was quantified using a bicinchoninic acid assay kit (Beyotime).

In this assay, an equal amount of protein extraction was separated by 10% sodium dodecyl sulfate polyacrylamide gel and then transferred into polyvinylidene fluoride membranes (Millipore, USA). Afterward, the membranes were blocked in 5% nonfat milk and cultured at room temperature for 1 h. The membranes were incubated overnight...
at 4°C with the following primary antibodies: anti-ATG5 antibodies (ab108327, Abcam, Cambridge, UK), anti-p62 antibodies (ab109012, Abcam), anti-LC3-I antibody (ab192890, Abcam), anti-LC3-II antibodies (ab192890, Abcam), anti-GAPDH (ab181602, Abcam), and anti-LDHA antibodies (ab101562, Abcam). Afterward, the membranes were incubated with secondary antibody goat anti-rabbit IgG (ab205718; Abcam). Finally, the enhanced chemiluminescence kit (GE Healthcare Bio-Sciences, Pitterburg, PA, USA) was utilized to visualize the proteins. Protein bands were detected by the Image J software (National Institutes of Health, Bethesda, MA) based on the intensity.

**Fluorescence In Situ Hybridization (FISH)**

The LINC01207 FISH probe was designed and synthesized by RiboBio (Guangzhou, China). Briefly, cells were seeded on coverslips, fixed with 4% paraformaldehyde for 15 min at 4°C, and permeabilized with 1% Triton X-100 for 30 min. Next, the coverslips were washed with 2 × SSC (300 mM NaCl, 30 mM sodium citrate, pH 7.0) for 30 min at 37°C and dehydrated with ethanol at room temperature. FISH probes in hybridization buffer were incubated with coverslips overnight at 37°C. Subsequently, coverslips were washed twice with 0.4 × SSC/0.3% Tween20 and 2 × SSC/0.1% Tween20, stained with 4’,6-Diamidino-2’-phenylindole, and then detected by a confocal fluorescence microscope (Leica, Germany) [37].

**Luciferase reporter assay**

The wild type (Wt) or mutant (Mut) sequence in the LDHA 3’UTR containing the predicted binding site for miR-1301-3p was synthesized to generate the fragment of LDHA-wild type (LDHA-Wt) and fragment of LDHA-mutant (LDHA-Mut). The targeted fragments were inserted into the pmirGLO vector (Promega, Madison, WI, USA). Then the recombinant plasmids (LDHA-Wt and LDHA-Mut) were transfected with miR-1301-3p mimics or NC mimics into cells, respectively. Similarly, miR-1301-3p-Wt/Mut plasmids were transfected with pcDNA3.1 or pcDNA3.1-LINC01207 into OSCC cells. After 48 h, the luciferase activity was examined using the Dual-luciferase Reporter Assay System (Promega) [38].

**RNA immunoprecipitation (RIP) assay**

RIP was performed using a Magna RNA-binding protein immunoprecipitation kit (EMD Millipore, Billerica, MA, USA) [39]. At 90% confluence, cells were centrifuged at 4°C for 5 min at 1,000 × g, washed with pre-cooled phosphate buffered saline and lysed with radioimmunoprecipitation assay lysis buffer. Subsequently, the lysates were incubated for 10 min at 4°C with human Ago2 antibody (ab186733; Abcam; 5 µg) conjugated on magnetic beads, with IgG antibody (ab172730; Abcam; 5 µg) as the control group. Samples were treated with Proteinase K for 30 min at 55°C with gentle agitation. Immunoprecipitated RNA was isolated using TRIzol. Co-precipitated RNAs were purified, identified, and analyzed with RT-qPCR.

**Statistical analysis**

Data were analyzed using SPSS 19.0 software (SPSS Inco, Chicago, IL, USA) and are presented as the mean ± standard deviation. One-way or two-way analysis of variance and student’s t-test were utilized to compare the differences between groups. Linear correlation analysis was performed using Spearman’s correlation coefficient. Data were statistically significance when p < 0.05.

**Results**

In this study, we investigated the biological role and studied the molecular mechanisms of LINC01207 in OSCC. Our data showed a significant upregulation of LINC01207 in OSCC tissues and cell lines. LINC01207 overexpression promoted the malignant phenotypes of OSCC cells, and inhibited cell apoptosis and autophagy. LINC01207 upregulated LDHA expression by acting as a ceRNA for miR1301-3p. Overall, our study demonstrated a functional role of the LINC01207/miR-1301-3p/LDHA axis in OSCC, implying that targeting these molecules could be a novel approach in OSCC treatment.
**LINC01207 is overexpressed in OSCC tissues and cells**

Given that OSCC is the most common type of head and neck cancer, we selected several lncRNAs (LINC00520, LINC00461, LINC00460, LINC00052, LINC00467, and LINC01207) that were reported to exert important effects in head and neck cancer to investigate the role of lncRNA in OSCC. RT-qPCR presented that LINC01207 expression was significantly upregulated in OSCC tumor tissues compared to that in adjacent normal tissues, while the other lncRNAs showed no significant changes (Figure 1(a)). Similarly, the higher level of LINC01207 in HSC-3 and HSC-4 cells than in NOK cells was also detected by RT-qPCR (Figure 1(b)). Therefore, we chose LINC01207 for the study.

**LINC01207 silencing inhibits OSCC cell growth and promotes apoptosis and autophagy**

To verify the function of LINC01207 in OSCC, the following assays were performed. After transfecting sh-NC or sh-LINC01207#1/2 into OSCC cells, as presented by RT-qPCR, LINC01207 expression was significantly downregulated in OSCC cells (Figure 2(a)). The CCK-8 assay demonstrated that after LINC01207 knockdown, the viability in HSC-3 and HSC-4 was inhibited (Figure 2(b)). Consistently, the number of colonies was decreased after transfection of sh-LINC01207#1/2 (Figure 2(c)). Transwell assay was used to examine the impact of LINC01207 in OSCC cell migration, and the results showed that the migration of HSC-3 and HSC-4 cells was significantly suppressed by LINC01207 knockdown (Figure 2(d)). Flow cytometry analysis showed that the apoptotic rate was increased in cells transfected with sh-LINC01207#1/2, which indicated that LINC01207 knockdown promotes OSCC cell apoptosis. (Figure 2(e)). We further performed western blot to test the change of autophagy. As shown, the protein expression of ATG5 and LC3-II was upregulated by LINC01207 silencing while that of P62 was downregulated, suggesting LINC01207 silencing promotes cell autophagy in

---

**Figure 1.** LINC01207 is overexpressed in OSCC tissues and cells. (a) RT-qPCR was conducted to detect the expression of LINC00520, LINC00461, LINC00460, LINC00052, LINC00467, and LINC01207 in OSCC tissues and adjacent normal tissues. (b) LINC01207 expression in NOK, HSC-3, and HSC-4 cells was measured using RT-qPCR. ***P < 0.001.
Figure 2. Effects of LINC01207 silencing on OSCC cells. (a) RT-qPCR was used to detect the LINC01207 level in HSC-3 and HSC-4 cells after transfecting sh-LINC01207#1/2. (b) CCK-8 assay was employed to assess cell viability in the transfected cells. (c) the number of colonies after transfection was detected using colony formation assay. (d) transwell assay was used to examine the impact of LINC01207 knockdown in OSCC cell migration. (e) cell apoptosis after transfection was evaluated by flow cytometry. (f) western blot was conducted for the detection of the expression of autophagy-related protein (ATG5, P62, LC3-I/II). *P < 0.05, **P < 0.01, ***P < 0.001.
OSCC (Figure 2(f)). We then assessed LINC01207 expression after transfection of pcDNA3.1-LINC01207 and found that LINC01207 was upregulated by pcDNA3.1-LINC01207 (Figure 3(a)). Experiments demonstrated that overexpression of LINC01207 significantly facilitated OSCC cell viability, proliferation, migration, and inhibited apoptosis and autophagy (Figure 3(b-f)). Therefore, LINC01207 acts as an oncogenic gene in OSCC.

**LINC01207 sponges miR-1301-3p**

Since the subcellular location determines how lncRNA regulates gene expression, we then detected subcellular location of LINC01207 by FISH assay. It was revealed that LINC01207 was significantly distributed in the cytoplasm of HSC-3 and HSC-4 cells (Figure 4(a)). LncRNAs in the cytoplasm are widely reported to function as ceRNAs via sponging miRNAs. The downstream miRNAs of LINC01207 were searched in DIANA (http://carolina.imis.athena-innovation.gr/diana_tools/web/index.php?r=lncbasev2/index-predicted). RT-qPCR presented the expression of miRNAs (miR-1301-3p, miR-4659b-3p, miR-4659a-3p, miR-5047, miR-6754-3p and miR-877-3p) that have predicted binding site for LINC01207, and the results showed that only miR-1301-3p was significantly downregulated in OSCC cells (Figure 4(b)). Additionally, the miR-1301-3p level was reduced after LINC01207 overexpression (Figure 4(c)). The binding site between LINC01207 and miR-1301-3p is presented (Figure 4(d)). Luciferase reporter assay demonstrated that the luciferase activity of pmirGLO-miR-1301-3p-Wt reporters was attenuated after overexpression of LINC01207; however, pmirGLO-miR-1301-3p-Mut reporters had no alteration in the luciferase activity, which suggested that LINC01207 can bind to miR-1301-3p (Figure 4(e)). Furthermore, correlation analysis showed that there was a negative correlation between LINC01207 and miR-1301-3p expression in OSCC tissues (Figure 4(f)). In summary, LINC01207 acts as a sponge of miR-1301-3p.

**LDHA is targeted by miR-1301-3p**

The potential targets of miR-1301-3p were predicted in starBase (http://starbase.sysu.edu.cn/) (search category: CLIP Data: strict stringency ≥5; Degradome Data: high stringency ≥3; Predicted Program: PicTar). RT-qPCR presented that LDHA expressed a significantly high level in OSCC cells (Figure 5(a)). Next, miR-1031-3p expression was elevated by using miR-1301-3p mimics (Figure 5(b)). The binding site between LDHA and miR-1301-3p is presented (Figure 5(c)). In HSC-3 and HSC-4 cells, we found that the luciferase activity of pmirGLO-LDHA 3’UTR-Wt was reduced when miR-1301-3p was overexpressed while no change was found in pmirGLO-LDHA 3’UTR-Mut, showing that LDHA is targeted by miR-1301-3p (Figure 5(d)). Western blot analysis revealed that both downregulation...
Figure 3. Effects of LINC01207 overexpression on OSCC cells. (a) RT-qPCR was used to detect the LINC01207 level in HSC-3 and HSC-4 cells after transfecting pcDNA3.1-LINC01207. (b) cell viability was detected by CCK-8 assay. (c) the number of colonies was detected using colony formation assay. (d) transwell assay was used to examine the impact of LINC01207 overexpression in cell migration. (e) cell apoptosis was evaluated by flow cytometry. (f) western blot was conducted to measure the expression of autophagy-related protein (ATG5, P62, LC3-I/II). *P < 0.05, **P < 0.01.
of LINC01207 and upregulation of miR-1301-3p decreased the LDHA protein level in HSC-3 and HSC-4 cells (Figure 5(e)). Furthermore, RIP assay demonstrated that LINC01207, miR-1301-3p, and LDHA were abundantly enriched in the Ago2 group compared to the IgG group (figure 5(f)). Overall, LINC01207 upregulates LDHA through controlling the availability of miR-1301-3p.

**P < 0.01.

**LDHA overexpression reverses the effects of LINC01207 knockdown in OSCC**

Since the ceRNA mechanism among LINC01207, miR-1301-3p and LDHA was verified, the rescue assays were in need. RT-qPCR and western blot analysis revealed that LDHA was strongly over-expressed by pcDNA3.1-LDHA in HSC-3 cells (Figure 6(a-b)). CCK-8 and colony formation
Figure 5. LDHA is targeted by miR-1301-3p. (a) the mRNA expression in OSCC cells was revealed by RT-qPCR. (b) the expression of miR-1301-3p in OSCC cells after transfection with NC mimics and miR-1301-3p mimics was assessed by RT-qPCR. (c) the binding site between miR-1301-3p and LDHA 3’UTR. (d) A luciferase reporter assay was conducted to evaluate the luciferase activity of pmirGLO-LDHA 3’UTR-Wt and pmirGLO-LDHA 3’UTR-Mut in OSCC cells after overexpression of miR-1301-3p. (e) the LDHA protein expression in OSCC cells after miR-1301-3p overexpression or LINC01207 downregulation was measured by western blot. (f) Ago-2 RIP assay was conducted to detect the enrichment of LINC01207, miR-1301-3p and LDHA in RNA-induced silencing complexes. **P < 0.01, ***P < 0.001.
assays showed that the cell viability and proliferation suppressed by LINCO1207 silencing were rescued by LDHA overexpression (Figure 6(c-d)). LINCO1207 depletion-mediated suppressive effects on HSC-3 cell migration were reduced after LDHA was overexpressed (Figure 6(e)). Flow cytometry analysis presented that LINCO1207 silencing promoted cell apoptosis while LDHA overexpression reversed the results (figure 6(f)). Moreover, the protein expression of ATG5 and LC3-II was upregulated by LINCO1207 silencing while was downregulated after LDHA overexpression, and the that of P62 showed an opposite result (Figure 6(g)). Overall, LINCO1207 promotes OSCC cellular process by elevating LDHA expression.

**Discussion**

In recent years, emerging evidence has revealed that lncRNAs are involved in OSCC progression [40,41]. Moreover, LINCO1207 was shown to be an oncogenic gene in tumor progression. LINCO1207 downregulation led to the promotion of cell apoptosis and the inhibition of proliferation in gastric cancer [20]. LINCO1207 inhibits prostate cancer cell apoptosis and promotes proliferation [24]. In our study, we discovered the overexpression of LINCO1207 in OSCC tissues and cells, implying its possible involvement in OSCC progression. We knocked down the expression of LINCO1207 in OSCC cells to examine its biological role. Our results revealed that LINCO1207 silencing inhibited OSCC cell
proliferation and migration but promoted cell apoptosis, and LINC01207 overexpression showed an opposite result. Additionally, a previous study demonstrated that LINC01207 silencing promotes autophagy in pancreatic cancer by increasing LC3II and beclin-1 protein expression while decreasing P62 expression [42]. Similarly, in our study, the inhibitory function of LINC01207 on OSCC cell autophagy was discovered. Therefore, these results suggested that LINC01207 promotes the progression of OSCC in vitro. Animal studies in the future are needed to further confirm whether LINC01207 exerts oncogenic effects in OSCC.

Accumulating evidence suggests that lncRNAs may act as ceRNAs for particular miRNAs to modulate the target genes of the miRNAs, including GC [43,44]. In this study, we assessed the subcellular localization of LINC01207 and observed that majority of LINC01207 were located in the cytoplasm of OSCC cells, which suggested that LINC01207 may function as a ceRNA for sponging miRNA. Thus, we predicted a miRNA that can interact with LINC01207 in OSCC cells and found that LINC01207 has a binding site for miR-1301-3p. MiR-1301-3p has been reported to be downregulated in many tumors and function as a tumor suppressor. Xu G et al. found in their study that miR-1301-3p upregulation significantly suppresses colorectal cancer cell growth [45]. The inhibitory effects of miR-1301-3p on breast cancer cell proliferation were found [46]. MiR-1301-3p is downregulated in papillary thyroid cancer and inhibits tumor growth [47]. In this study, we also found that miR-1301-3p was significantly downregulated in OSCC cells, and its expression was negatively correlated to LINC01207 expression. Thus, LINC01207 may play a role in OSCC by sponging miR-1301-3p.

Generally, as a ceRNA, the function of lncRNAs depends on the miRNA targets. LDHA was selected as a direct target of miR-1301-3p through bioinformatics analysis and luciferase reporter assay. LDHA has a key role in tumor cell metabolism and adaptation to unfavorable environmental or cellular conditions [48]. LDHA is overexpressed in prostate cancer and induces a favorable microenvironment for tumor progression [49]. With the deepening of research, our study revealed that LDHA was overexpressed in OSCC cells. Additionally, rescue experiments revealed that LDHA overexpression could rescue the effects caused by knockdown of LINC01207 in OSCC. Moreover, it was reported that LDHA promotes tumorigenesis by facilitating glycolysis and epithelial-mesenchymal transition in OSCC [50], implying the oncogenic property of LDHA in OSCC. Thus, these results demonstrated that LINC01207 acts as a sponge for miR-1301-3p and upregulates the expression of its endogenous target LDHA in OSCC. However, our study has some limitations. The interactions between cytokines in cancer cells are complex, and whether LINC01207 regulates other potential mechanisms will be examined. Additionally, the sample size will be increased to verify the associations between LINC01207 and the prognosis of patients with OSCC.

**Conclusion**

Overall, we demonstrated that LINC01207 is upregulated in OSCC tissues and cells. LINC01207 upregulates LDHA expression to promote OSCC cell proliferation, migration, and inhibit apoptosis and autophagy by acting as a ceRNA that sponges miR-1301-3p. Our results provide inspiration for further understanding of the mechanisms of OSCC. In the future work, we will explore the mechanisms of LINC01207 upregulation in OSCC, the correlations between LINC01207 and other miRNAs or proteins, which will further deepen our understanding of the pathogenesis of LINC01207 and make LINC01207 a potential novel diagnostic and therapeutic target for OSCC.

**Disclosure statement**

No potential conflict of interest was reported by the author(s).

**Funding**

This work was supported by Nanjing Medical Science and Technique Development Foundation (No. QXR17175).

**ORCID**

Fangfang Sun http://orcid.org/0000-0002-7322-2566
References

[1] Le F, Ou Y, Luo P, et al. LncRNA NCK1-AS1 in plasma distinguishes oral ulcer from early-stage oral squamous cell carcinoma. J Biol Res (Thessalon). 2020 Dec;27 (1):16.

[2] Yao C, Kong F, Zhang S, et al. Long non-coding RNA BANCR promotes proliferation and migration in oral squamous cell carcinoma via MAPK signaling pathway. J Oral Pathol Med. 2021 Mar;50(3):308–315.

[3] Modesto A, Siefried A, Lusque A, et al. Distinct Outcomes of Oropharyngeal Squamous Cell Carcinoma Patients after Distant Failure According to p16 Status: implication in Therapeutic Options. Curr Oncol. 2021 Apr 29;28(3):1673–1680.

[4] Ac C, Ta D, BW N. Oral cavity and oropharyngeal squamous cell carcinoma—an update. CA Cancer J Clin. 2015 Sep-Oct;65(5):401–421.

[5] Sasahira T, Kirita T. Hallmarks of Cancer-Related Newly Prognostic Factors of Oral Squamous Cell Carcinoma. Int J Mol Sci. 2018 16;19(8):Aug.

[6] Wang W, Tan J. Co-inhibition of BET proteins and PD-L1 as a potential therapy for OSCC through synergistic inhibition of FOXM1 and PD-L1 expressions. J Oral Pathol Med. 2019 Oct;48(9):817–825.

[7] Miller K, McGrath ME, Hu Z, et al. Coronavirus interactions with the cellular autophagy machinery. Autophagy. 2020 Dec;16(12):2131–2139.

[8] Klionsky DJ, Abdel-Aziz AK, Abdelfatah S, et al. Guidelines for the use and interpretation of assays for monitoring autophagy(4th edition)(1). Autophagy. 2021 Jan;17(1):1–382.

[9] Xiong J, Kong Q, Dai L, et al. Autophagy activated by tuberin/mTOR/p70S6K suppression is a protective mechanism against local anaesthetics neurotoxicity. J Cell Mol Med. 2017 Mar;21(3):579–587.

[10] Klionsky DJ, Abdellomshen K, Abe A, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy. 2016;12(1):1–222.

[11] Montiel T, Montes-Ortega LA, Flores-Yáñez S, et al. Treatment with the Ketone Body D-β-hydroxybutyrate Attenuates Autophagy Activated by NMDA and Reduces Excitotoxic Neuronal Damage in the Rat Striatum In Vivo. Curr Pharm Des. 2020;26 (12):1377–1387.

[12] Amaravadi R, Kimmelman AC, White E. Recent insights into the function of autophagy in cancer. Genes Dev. 2016 Sep 1;30(17):1913–1930.

[13] Choudhari R, Sedano MJ, Harrison AL, et al. Long noncoding RNAs in cancer: from discovery to therapeutic targets. Adv Clin Chem. 2020;95:105–147.

[14] Noh JH, Kim KM, McClusky WG, et al. Cytoplasmic functions of long noncoding RNAs. Wiley Interdiscip Rev RNA. 2018 May;9(3):e1471.

[15] Kopp F, JT M. Functional Classification and Experimental Dissection of Long Noncoding RNAs. Cell. 2018 Jan 25;172(3):393–407.

[16] Huarte M. The emerging role of lncRNAs in cancer. Nat Med. 2015 Nov;21(11):1253–1261.

[17] Jiang L, Ge W, Cui Y, et al. The regulation of long non-coding RNA 00958 (LINC00958) for oral squamous cell carcinoma (OSCC) cells death through absent in melanoma 2 (AIM2) depending on microRNA-4306 and Sirtuin1 (SIRT1) in vitro. Bioengineered. 2021 Dec;12(1):5085–5098.

[18] Zhu X, Zhang H, Xu J. Long noncoding RNA SNHG20 regulates cell migration, invasion, and proliferation via the microRNA-19b-3p/RAB14 axis in oral squamous cell carcinoma. Bioengineered. 2021 Dec;12(1):3993–4003.

[19] Liu H, Liu X. LINC01207 is up-regulated in gastric cancer tissues and promotes disease progression by regulating miR-671-5p/DDX5 axis. J Biochem. 2021 Apr;15.

[20] Yu L, Gao Y, Ji B, et al. CTCF-induced upregulation of LINC01207 promotes gastric cancer progression via miR-1301-3p/PODXL axis. Dig Liver Dis. 2021 Apr;53(4):486–495.

[21] Wu K, Jiang Y, Zhou W, et al. Long Noncoding RNA RC3H2 Facilitates Cell Proliferation and Invasion by Targeting MicroRNA-101-3p/EZH2 Axis in OSCC. Mol Ther Nucleic Acids. 2020 Jun;520:97–110.

[22] Xia YC, Cao J, Yang J, et al. lncRNA TSPEAR-AS2, a Novel Prognostic Biomarker, Promotes Oral Squamous Cell Carcinoma Progression by Upregulating PPM1A via Sponging miR-487a-3p. Dis Markers. 2021;2021:217663.

[23] Chen C, Jiang L, Zhang Y, et al. FOXA1-induced LINC01207 facilitates head and neck squamous cell carcinoma via up-regulation of TNRC6B. Biomed Pharmacother. 2020 Aug;128:110220.

[24] Wang S, Qiu J, Wang L, et al. Long non-coding RNA LINC01207 promotes prostate cancer progression by downregulating microRNA-1972 and upregulating LIM and SH3 protein 1. JUBMB Life. 2020 Sep;72 (9):1960–1975.

[25] Zhao D, Zou SW, Liu Y, et al. Lysine-5 acetylation negatively regulates lactate dehydrogenase A and is decreased in pancreatic cancer. Cancer Cell. 2013 Apr 15;23(4):464–476.

[26] Shi M, Cui J, Du J, et al. A novel KLF4/LDHA signaling pathway regulates aerobic glycolysis in and progression of pancreatic cancer. Clin Cancer Res. 2014 Aug 15;20(16):4370–4380.

[27] Crane CA, Austgen K, Haberthür K, et al. Immune evasion mediated by tumor-derived lactate dehydrogenase induction of NKG2D ligands on myeloid cells in glioblastoma patients. Proc Natl Acad Sci U S A. 2014 Sep 2;111(35):12823–12828.

[28] Kim J, Han J, Jang Y, et al. High-capacity glycolytic and mitochondrial oxidative metabolisms mediate the growth ability of glioblastoma. Int J Oncol. 2015 Sep;47(3):1009–1016.

[29] Fantin VR, St-Pierre J, Leder P. Attenuation of LDH-A expression uncovers a link between glycolysis,
mitochondrial physiology, and tumor maintenance. Cancer Cell. 2006 Jun;9(6):425–434.

[30] Li J, Chen Y, Qin X, et al. MiR-138 downregulates miRNA processing in HeLa cells by targeting RMND5A and decreasing Exportin-5 stability. Nucleic Acids Res. 2014 Jan;42(1):458–474.

[31] Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008;3(6):1101–1108.

[32] Zhao L, Li J, Sun ZB, et al. Saikosaponin D inhibits proliferation of human osteosarcoma cells via the p53 signaling pathway. Exp Ther Med. 2019 Jan;17(1):488–494.

[33] Hong Z, Wang Z, Zhou B, et al. Effects of evodiamine on PI3K/Akt and MAPK/ERK signaling pathways in pancreatic cancer cells. Int J Oncol. 2020 Mar;56(3):783–793.

[34] Yao J, Wang C, Dong X, et al. IncRNA SNHG22 sponges miR-128-3p to promote the progression of colorectal cancer by upregulating EZF3. Int J Oncol. 2021 Sep;59(3). DOI: 10.3892/ijo.2021.5251.

[35] Azizi R, Salemi Z, Fallahian F, et al. Inhibition of didscoidin domain receptor 1 reduces epithelial-mesenchymal transition and induce cell-cycle arrest and apoptosis in prostate cancer cells. J Cell Physiol. 2019 Nov;234(11):19539–19552.

[36] Tam SY, Wu VWC, Law HKW. JNK Pathway Mediates Low Oxygen Level Induced Epithelial-Mesenchymal Transition and Stemness Maintenance in Colorectal Cancer Cells. Cancers (Basel). 2020 16;12(1):Jan.

[37] Zhang Z, Chen F, Zhan H, et al. IncRNA CASC9 sponges miR-758-3p to promote proliferation and EMT in bladder cancer by upregulating TGF-β2. Oncol Rep. 2021 Jan;45(1):265–277.

[38] Sato C, Yamamoto Y, Funayama E, et al. Conditioned Medium Obtained from Amnion-Derived Mesenchymal Stem Cell Culture Prevents Activation of Keloid Fibroblasts. Plast Reconstr Surg. 2018 Feb;141(2):390–398.

[39] Wen R, Chen C, Zhong X, et al. PAX6 upstream antisense RNA (PAUPAR) inhibits colorectal cancer progression through modulation of the microRNA (miR)-17-5p/zinc finger protein 750 (ZNF750) axis. Bioengineered. 2021 Dec;12(1):3886–3899.

[40] Xiong HG, Li H, Xiao Y, et al. Long noncoding RNA MYOSLID promotes invasion and metastasis by modulating the partial epithelial-mesenchymal transition program in head and neck squamous cell carcinoma. J Exp Clin Cancer Res. 2019 Jun 25;38(1):278.

[41] Zhang S, Tian L, Ma P, et al. Potential role of differentially expressed IncRNAs in the pathogenesis of oral squamous cell carcinoma. Arch Oral Biol. 2015 Oct;60 (10):1581–1587.

[42] Liu C, Wang JO, Zhou WY, et al. Long non-coding RNA LINC01207 silencing suppresses AGR2 expression to facilitate autophagy and apoptosis of pancreatic cancer cells by sponging miR-143-5p. Mol Cell Endocrinol. 2019 Aug 1;493:110424.

[43] Jiang X, Liu J, Li S, et al. CCL18-induced LINC00319 promotes proliferation and metastasis in oral squamous cell carcinoma via the miR-199a-5p/FZD4 axis. Cell Death Dis. 2020 Sep 18;11(9):777.

[44] Li S, Chen X, Liu X, et al. Complex integrated analysis of IncRNAs-miRNAs-mRNAs in oral squamous cell carcinoma. Oral Oncol. 2017 Oct;73:1–9.

[45] Xu G, Wang H, Yuan D, et al. RUNX1-activated upregulation of IncRNA RNCR3 promotes cell proliferation, invasion, and suppresses apoptosis in colorectal cancer via miR-1301-3p/AKT1 axis in vitro and in vivo. Clin Transl Oncol. 2020 Oct;22 (10):1762–1777.

[46] Peng X, Yan B, Shen Y. MiR-1301-3p inhibits human breast cancer cell proliferation by regulating cell cycle progression and apoptosis through directly targeting ICT1. Breast Cancer. 2018 Nov;25(6):742–752.

[47] Qiao DH, He XM, Yang H, et al. miR-1301-3p suppresses tumor growth by downregulating PCNA in thyroid papillary cancer. Am J Otolaryngol. 2021 Mar-Apr;42(2):102920.

[48] Urbaniska K, Orzechowski A. Unappreciated Role of LDHA and LDHB to Control Apoptosis and Autophagy in Tumor Cells. Int J Mol Sci. 2021 Apr 27;20(9):9.

[49] Xian ZY, Liu JM, Chen QK, et al. Inhibition of LDHA suppresses tumor progression in prostate cancer. Tumour Biol. 2015 Sep;36(10):8093–8100.

[50] Cai H, Li J, Zhang Y, et al. LDHA Promotes Oral Squamous Cell Carcinoma Progression Through Facilitating Glycolysis and Epithelial-Mesenchymal Transition. Front Oncol. 2019;9:1446.